| 发明名称 |
Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
| 摘要 |
This invention relates to a method for managing the risk of an adverse interaction between teriflunomide and a substrate of breast cancer resistance protein (BCRP) and/or organic anion transporting polypeptide B1 and B3 (OATP1B1/B3). |
| 申请公布号 |
US9186346(B2) |
申请公布日期 |
2015.11.17 |
| 申请号 |
US201414172082 |
申请日期 |
2014.02.04 |
| 申请人 |
SANOFI |
发明人 |
Weitz Dietmar;Menguy-Vacheron Francoise;Clot Pierre-Francois;Turpault Sandrine |
| 分类号 |
A61K31/275;A61K31/505;A61K31/277 |
主分类号 |
A61K31/275 |
| 代理机构 |
|
代理人 |
Lin Jiang |
| 主权项 |
1. A method for treating multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction in a patient having multiple sclerosis, wherein rosuvastatin is co-administered with teriflunomide, comprising administering to the patient about 7 or 14 mg of teriflunomide daily, and administering to the patient rosuvastatin which is at the amount of about 50% of the normal dose of rosuvastatin. |
| 地址 |
Paris FR |
